Urothelial Carcinoma Treatment Market Regional Analysis:
North American Market Insights
North America industry is set to account for largest revenue share of 38% by 2035. The growth of the market can be attributed majorly to the increasing frequency of urothelial carcinoma cancer in the region. Cigarette smoking continues to be the largest cause of avoidable illness, disability, and death in the area. There are presently more than 30 million adult smokers in the US. Additionally, males smoke more frequently than females do, and black people smoke more frequently than white people. Furthermore, in the USA, smoking has a significant negative economic impact. The majority of the direct costs associated with tobacco use come from medical expenses to treat associated diseases and lost productivity as a result of sickness and early mortality. Every year, bladder cancer causes 17,000 fatalities and 80,000 new cases in the United States.
Europe Market Insights
The European urothelial carcinoma treatment market, amongst the market in all the other regions, is projected to grow with the highest CAGR during the forecast period. The growth of the market can be attributed majorly to the increasing incidence of urothelial cancer in various European economies. Among the 28 European Union member states, bladder cancer affects more than 120 000 individuals each year (EU). It is the sixth most common cancer cause, taking the lives of more than 40 000 people each year. For instance, owing to a higher frequency of smoking and an older population, incidence rates of bladder cancer have been rising in Germany and Bulgaria, and are predicted to continue rising. Additionally, in Germany, 3-4% of all malignant tumors are bladder carcinomas, and around 15,000 individuals are diagnosed with bladder cancer each year, making it the fourth most frequent malignancy among males. They are more common in those over the age of 70. Moreover, there has been a rising number of bladder cancer cases, including metastatic bladder cancer, that is further anticipated to rise the market’s growth in the region. Further, Southern Europe has the greatest prevalence of bladder cancer among females.
